AMENDMENTS TO THE CALIMS

This Listing of the Claims will replace all prior versions and listings of claims in the application.

1. (Currently Amended) A compound of formula I



I

wherein

R_a is H, C_{1-4}alkyl, or C_{1-4}alkyl substituted by OH, NH_2, NHC_{1-4}alkyl or $N(di\text{-}C_{1-4}alkyl)_2$;

one of R_b, R_c, R_d and R_e is halogen, C_{1-4}alkoxy, or C_{1-4}alkyl, and the other three substituents are H; or R_b, R_c, R_d and R_e are all H; and

R is a radical of formula (a)



(a)

wherein

R_1 is $-(CH_2)_n-NR_3R_4$, wherein

each of R_3 and R_4, independently, is H or C_{1-4}alkyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue;

n is 0, 1 or 2; and

R_2 is H, halogen, C_{1-4}alkyl, CF_3, OH, SH, NH_2, NO_2, C_{1-4}alkoxy, C_{1-4}alkylthio, NHC_{1-4}alkyl, $N(di\text{-}C_{1-4}alkyl)_2$ or CN;

or a salt thereof.

2. (Currently Amended) A compound according to claim 1 wherein R_a is H or methyl; one of R_b, R_c, R_d and R_e is methyl or ethyl and the other three substituents are H; or R_b, R_c, R_d and R_e are all H; R_2 is H, Cl, methyl or NO_2; n is 1; and each of R_3 and R_4, independently, is H, methyl, ethyl or *i*-propyl; or R_3 and R_4 form together with the nitrogen atom to which they are bound a heterocyclic residue, or a salt thereof.

3. (Original) A compound according to claim 1 or 2 which is selected from

3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-methylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-dimethylaminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(2-Chloro-6-methylaminomethyl -naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(1H-indol-3-yl)-pyrrole-2,5-dione;
3-(6-Aminomethyl-naphthalen-1-yl)-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione; or a salt thereof.

4. (Original) A compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.

5. (Original) A pharmaceutical composition comprising a compound according to any one of claim 1 to 3, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.

6. (Original) Use of a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treating or preventing diseases or disorders mediated by T lymphocytes and/or PKC.

7. (Original) Use of a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 5 in the manufacture of a medicament for treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection, cancer or infectious diseases.

8. (Original) A pharmaceutical combination comprising a compound according to any one of claim 1 to 3, in free form or in a pharmaceutically acceptable salt form, and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic, antiproliferative and anti-diabetic agents.

9. (Currently Amended) A process for the production of the compound of formula I according to claim 1 or claim 2, which process comprises reacting a compound of formula II



II

wherein R_a, R_b, R_c, R_d and R_e are as defined in claim 1 and claim 2,

with a compound of formula III

$$R - CH_2 - CO - NH_2 \qquad (III)$$

wherein R is as defined in claim 1 and claim 2,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

10. (Original) A method for treating or preventing disorders or diseases mediated by T lymphocytes and/or PKC, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to any one of claim 1 to 3, or a pharmaceutically acceptable salt thereof.